[SCHEDULE 13G] Sagimet Biosciences Inc. Series A SEC Filing

Rhea-AI Filing Summary

Woodline Partners LP disclosed beneficial ownership of 2,552,536 shares of Sagimet Biosciences Series A common stock, representing approximately 8.3% of the outstanding class. The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, and the reporting page shows Woodline Partners has sole voting and dispositive power over these shares.

The filing was made on Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not purchased to change or influence control of the issuer. The percentage is calculated using an aggregate share base of about 30,674,855 shares reported in the company’s quarterly report for the period ended March 31, 2025.

Positive

• Material disclosed stake: Reporting of 2,552,536 shares (~8.3%) is a clear, material ownership disclosure
• Clear control authority: Reporting person states sole voting and dispositive power over the shares
• Schedule 13G certification: Filing includes a certification that the shares were acquired and are held in the ordinary course of business and not to influence control

Negative

• None.

Insights

Financial Analyst

Woodline holds a material passive stake ~8.3%, disclosed via Schedule 13G; no stated intent to seek control.

Holding 2,552,536 shares, equal to roughly 8.3% of the reported ~30.7 million share class, is large enough to be material for investors and can affect float and voting outcomes. The Schedule 13G form and the included certification indicate Woodline views this as a passive, ordinary-course position rather than an activist or control-seeking stake. For analysts, the key points are the stake size, sole voting/dispositive power, and the public acknowledgment that the position is not intended to influence control.

Corporate Governance Expert

An >5% disclosure is governance-relevant; Schedule 13G signals passive ownership but still warrants monitoring for voting impact.

From a governance perspective, a declared 8.3% holder with sole voting authority can be influential on shareholder votes, even if the filer asserts passive intent. The filing identifies Woodline Partners as the investment adviser to the fund that directly holds the shares and explicitly states the securities are held in the ordinary course of business and not to influence control. While Schedule 13G filings typically reflect non-activist positions, boards and investors commonly note such stakes because they change the ownership landscape and could mobilize in future corporate actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Sagimet Biosciences Inc.

(Name of Issuer)

Series A Common Stock, par value $0.0001 per share

(Title of Class of Securities)

786700104

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 786700104

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,552,536.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,552,536.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,552,536.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.3 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sagimet Biosciences Inc.
(b)	Address of issuer's principal executive offices: 155 Bovet Road, Suite 303, San Mateo, CA 94402
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of series A common stock, par value $0.0001 per share ("Series A Common Stock") of Sagimet Biosciences Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Series A Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Series A Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 786700104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of approximately 30,674,855 shares of Series A Common Stock outstanding as of May 2, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025.
(b)	Percent of class: 8.3%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	08/14/2025

FAQ

How many Sagimet (SGMT) shares does Woodline Partners report owning?

Woodline Partners reports beneficial ownership of 2,552,536 shares of Sagimet Series A common stock.

What percentage of SGMT does the reported stake represent?

The reported position represents approximately 8.3% of the Series A common stock outstanding.

Is Woodline Partners claiming control of Sagimet (SGMT)?

No. The Schedule 13G filing includes a certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control.

Through which vehicle does Woodline hold the SGMT shares?

The shares are directly held by Woodline Master Fund LP, for which Woodline Partners LP serves as investment adviser.

What share count was used to calculate the 8.3% figure?

The percentage is calculated using an aggregate of approximately 30,674,855 shares of Series A common stock reported in the company’s quarterly report for the period ended March 31, 2025.